Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 53 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantTerminatedNCT06271616Phase 2
• Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AMLTerminatedNCT06268574Phase 2
• Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerActive, not recruitingNCT06268210Phase 2
• A Study of TAK-279 in Healthy Adults on the Effect on ECG MeasurementsCompletedNCT06258265Phase 1
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06254950Phase 2
• Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06251180Phase 1
• A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer StudiesActive, not recruitingNCT06246643Phase 2
• A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)Active, not recruitingNCT06240351Phase 4
• HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic CholangiocarcinomaActive, not recruitingNCT06239532Phase 2
• A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid TumorsCompletedNCT06231550Phase 1
• Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).WithdrawnNCT06227897Phase 2
• Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)TerminatedNCT06222034Phase 1
• A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male ParticipantsCompletedNCT06221475Phase 1
• Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid TumorsActive, not recruitingNCT06220318Phase 1/2
• Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)SuspendedNCT06214793Phase 2
• A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib CreamCompletedNCT06213831Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult ParticipantCompletedNCT06213818Phase 1
• A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06212999Phase 3
• Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Phase 2
• A SHR0302 BA Study on Healthy SubjectsCompletedNCT06202612Phase 1
• Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and IrinotecanActive, not recruitingNCT06199973Phase 3
• To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR MutationsActive, not recruitingNCT06194448Phase 2
• Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)TerminatedNCT06191796Phase 1
• A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC PatientsTerminatedNCT06186076Phase 1/2
• Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia RheumaticaCompletedNCT06172361Phase 3
• caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.Active, not recruitingNCT06171854Phase 2
• A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaCompletedNCT06164951Phase 3
• A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoActive, not recruitingNCT06163326Phase 3
• A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine TumorsTerminatedNCT06158516Phase 2
• Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept StudyActive, not recruitingNCT06158113Phase 2
• Efficacy and Safety of Oral Tofacitinib in the Treatment of Alopecia AreataCompletedNCT06157905Early Phase 1
• An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604CompletedNCT06157255Phase 1
• Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentActive, not recruitingNCT06151574Phase 3
• An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®CompletedNCT06145217Phase 1
• A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Active, not recruitingNCT06140836Phase 3
• Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular CarcinomaActive, not recruitingNCT06138769Phase 2
• A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory GenodermatosesCompletedNCT06136403Phase 2
• A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the BrainActive, not recruitingNCT06132945Phase 1
• The Mass Balance Study of LP-168 in Healthy SubjectsCompletedNCT06126861Phase 1
• A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesCompletedNCT06120075Phase 1
• A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With VitiligoActive, not recruitingNCT06118411Phase 3
• A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid TumorsActive, not recruitingNCT06116240Phase 1
• Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)TerminatedNCT06114940Phase 2
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)Active, not recruitingNCT06113471Phase 3
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)Active, not recruitingNCT06113445Phase 3
• A Study of TAK-279 in Healthy Chinese AdultsCompletedNCT06111547Phase 1
• A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerActive, not recruitingNCT06110793Phase 1/2
• Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerActive, not recruitingNCT06109467Phase 2
• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment PeriodCompletedNCT06108544Phase 3
• Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult ParticipantsCompletedNCT06106074Phase 1
• A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).Active, not recruitingNCT06105619Phase 2/3
• A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple SclerosisWithdrawnNCT06104683Phase 2
• A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid ArthritisCompletedNCT06099535Phase 2
• Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)CompletedNCT06099184Phase 2
• Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM PatientsCompletedNCT06095375Phase 1
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)Active, not recruitingNCT06095128Phase 4
• Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met ProteinWithdrawnNCT06093503Phase 3
• A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male ParticipantsCompletedNCT06088264Phase 1
• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of TreatmentCompletedNCT06088043Phase 3
• Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.Active, not recruitingNCT06087263Phase 2
• A Study of LNK01001 Capsule in Patients With Ankylosing SpondylitisCompletedNCT06085534Phase 2
• A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic DermatitisCompletedNCT06085521Phase 2
• DZD9008 PK Study in Hepatic Impairment SubjectsCompletedNCT06084104Phase 1
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerActive, not recruitingNCT06083857Phase 1/2
• Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid CancersCompletedNCT06083662Phase 2
• TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06082635Phase 3
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06082167Phase 2/3
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT06073821Phase 3
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2Active, not recruitingNCT06072183Phase 3
• AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCWithdrawnNCT06068153Phase 2
• Zanubrutinib in Primary Cold Agglutinin DiseaseActive, not recruitingNCT06067048Phase 2
• Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCCStatus unknownNCT06059885Phase 2
• Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR InhibitorActive, not recruitingNCT06057571Phase 2
• Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINESuspendedNCT06055621Phase 2
• Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy SubjectsCompletedNCT06043739Phase 1
• Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.Active, not recruitingNCT06042478Phase 3
• Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)CompletedNCT06036836Phase 2
• Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLCActive, not recruitingNCT06031558Phase 3
• Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.CompletedNCT06030895Not applicable
• A Study to Evaluate Drug-Drug Interaction of TQ05105 TabletsCompletedNCT06024915Phase 1
• Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABACompletedNCT06020014Phase 2
• Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.Status unknownNCT06018688Phase 2
• Senolytics to Improve Osteoporosis TherapyCompletedNCT06018467Phase 2
• A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)Active, not recruitingNCT06015503Phase 2
• Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung CarcinomaSuspendedNCT06014827Phase 2
• Effect of Food on the Pharmacokinetics of ORIC-114CompletedNCT06012721Phase 1
• A Study of Lorlatinib in Combination With Ramucirumab in People With Lung CancerActive, not recruitingNCT06007937Phase 1/2
• Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal CancerTerminatedNCT06006923Phase 2
• A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult ParticipantsActive, not recruitingNCT06006702Phase 1
• A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy VolunteersCompletedNCT06004921Phase 1
• A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand EczemaCompletedNCT06004050Phase 3
• A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy AdultsCompletedNCT05995249Phase 1
• Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic LeukemiaActive, not recruitingNCT05993949Phase 1
• A Study of TAK-279 in Adults With or Without Kidney ProblemsCompletedNCT05992155Phase 1
• Multicenter Trial of ESK981 in Patients With Select Solid TumorsActive, not recruitingNCT05988918Phase 2
• IN10018 Combination Therapy in Previously-treated Solid TumorsWithdrawnNCT05982522Phase 1/2
• To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult SubjectsCompletedNCT05982106Phase 1
• A Study of TAK-279 in Adults With or Without Liver DamageCompletedNCT05976321Phase 1
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesActive, not recruitingNCT05976243Phase 3
• A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).TerminatedNCT05975645Phase 1

← Tyrosine Kinase Inhibitors overview